World Investment Advisors Has $4.76 Million Holdings in Astrazeneca Plc $AZN

World Investment Advisors boosted its holdings in shares of Astrazeneca Plc (NYSE:AZN) by 108.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 27,098 shares of the company’s stock after buying an additional 14,127 shares during the quarter. World Investment Advisors’ holdings in Astrazeneca were worth $4,756,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. IHT Wealth Management LLC grew its position in shares of Astrazeneca by 0.3% in the fourth quarter. IHT Wealth Management LLC now owns 17,527 shares of the company’s stock valued at $3,076,000 after purchasing an additional 54 shares during the last quarter. Visionary Wealth Advisors grew its position in shares of Astrazeneca by 1.5% in the fourth quarter. Visionary Wealth Advisors now owns 4,197 shares of the company’s stock valued at $737,000 after purchasing an additional 60 shares during the last quarter. Vista Investment Management grew its position in shares of Astrazeneca by 0.3% in the fourth quarter. Vista Investment Management now owns 21,215 shares of the company’s stock valued at $3,723,000 after purchasing an additional 60 shares during the last quarter. Kestra Investment Management LLC grew its position in shares of Astrazeneca by 1.9% in the fourth quarter. Kestra Investment Management LLC now owns 3,391 shares of the company’s stock valued at $595,000 after purchasing an additional 63 shares during the last quarter. Finally, Luken Investment Analytics LLC grew its position in shares of Astrazeneca by 4.3% in the fourth quarter. Luken Investment Analytics LLC now owns 1,564 shares of the company’s stock valued at $274,000 after purchasing an additional 64 shares during the last quarter. Institutional investors and hedge funds own 20.35% of the company’s stock.

Astrazeneca Trading Up 3.1%

Shares of AZN stock opened at $181.72 on Friday. The company has a current ratio of 0.91, a quick ratio of 0.71 and a debt-to-equity ratio of 0.52. The stock has a market cap of $281.83 billion, a P/E ratio of 27.29, a price-to-earnings-growth ratio of 1.51 and a beta of 0.25. The stock has a 50 day simple moving average of $190.77 and a 200 day simple moving average of $184.71. Astrazeneca Plc has a 1 year low of $137.23 and a 1 year high of $212.71.

Astrazeneca (NYSE:AZN) last issued its quarterly earnings results on Wednesday, April 29th. The company reported $2.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.52 by $0.06. The business had revenue of $15.29 billion during the quarter, compared to analysts’ expectations of $14.93 billion. Astrazeneca had a return on equity of 30.86% and a net margin of 17.19%. On average, research analysts predict that Astrazeneca Plc will post 9.52 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the company. Jefferies Financial Group reaffirmed a “buy” rating on shares of Astrazeneca in a research report on Wednesday, May 13th. TD Cowen reaffirmed a “buy” rating on shares of Astrazeneca in a research report on Wednesday, March 18th. Wall Street Zen raised Astrazeneca from a “hold” rating to a “buy” rating in a research report on Saturday, May 2nd. DZ Bank raised Astrazeneca from a “neutral” rating to a “buy” rating in a research report on Wednesday, April 29th. Finally, Sanford C. Bernstein reaffirmed a “buy” rating on shares of Astrazeneca in a research report on Monday, May 4th. Twelve research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $205.33.

About Astrazeneca

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.